Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Diamond LE, Earle DC, Garcia WD, et al. · Urology
Low-dose intranasal PT-141 (bremelanotide) combined with sildenafil produced an enhanced erectile response versus either agent alone, demonstrating central melanocortin involvement in penile erection.
Investigated as a clinical (men with erectile dysfunction) in the field of dermatological research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.
Low-dose intranasal PT-141 (bremelanotide) combined with sildenafil produced an enhanced erectile response versus either agent alone, demonstrating central melanocortin involvement in penile erection.
Bremelanotide is a closely related melanocortin agonist, not Melanotan-II; safety in chronic dosing and broader populations was not addressed.
- · PubMed: PMID 15833522 ↗
- · DOI: 10.1016/j.urology.2004.10.060 ↗
- · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
- · Google Scholar: scholar.google.com ↗